{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.4","value":"-1.8"},{"groupId":"OG001","spread":"1.5","value":"-1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \\[28 joints\\], swollen joint count (SJC) \\[28 joints\\], patient's global assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\] and C-Reactive Protein (CRP) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Re-treatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Re-treatment"}],"paramType":"MEAN","populationDescription":"Participants from the Intent-to-treat population that includes all participants randomized to Retreatment with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 48","title":"Change From Baseline in Disease Activity Score (DAS28-CRP) at Week 48","type":"SECONDARY","unitOfMeasure":"Units on a scale"}